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Abstract
Purpose The purpose of this study was to review a single-
institution experience with the reirradiation of recurrent
salivary gland tumors using fractionated stereotactic radio-
surgery (SBRT).
Methods Between 2003 and 2011, 18 patients diagnosed
with recurrent, previously irradiated, salivary gland carcino-
mas were treated with SBRT reirradiation. Median age was
68 for all patients with most tumors being of major salivary
gland origin. Most patients did not undergo surgical resec-
tion, and among those that did, all had positive margins.
Only seven patients received chemotherapy, and the median
SBRT dose was 30 Gy given in five fractions with a median
cumulative dose of 91.1 Gy.
Results The median overall survival (OS), progression-free
survival (PFS), and local control (LRC) were 11.5, 3.5, and
5.5 months, respectively. The 2-year OS, PFS, and LRC rates
were 39%, 24%, and 53%, respectively. Statistical analysis
identified presence of gross disease and interval to reirradiation
as negative predictors of survival outcomes on both univariate
and multivariate analyses (p < 0.05). On multivariate analysis,
tumor volume was a negative predictor of survival outcomes
(p < 0.05). Long-term toxicity analysis revealed four patients
in the reirradiated group with soft tissue necrosis, which cor-
related with the cumulative dose (p = 0.01).
Conclusion Our data suggest that SBRT is a reasonable
treatment option for reirradiation of salivary gland tumors,
but further studies are warranted.
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Introduction
Salivary gland cancers are rare, comprising only 3–5% of all
head and neck cancers, with a diverse spectrum of histologic
subtypes and natural history [1]. Multiple retrospective studies
have shown that in high-grade tumors, advanced stage (T3/4),
and/or inadequately excised tumors, adjuvant RT is superior to
surgery alone [2–5]. For patients with recurrent salivary gland
tumors, the prognosis is poor, largely because effective salvage
treatment is often limited by the infiltrative pattern of local
growth as well as the proximity of the recurrent tumor to critical
structures [6]. Since a large proportion of these patients have
previously received radiation therapy, the potential for severe
complications often prohibits the delivery of additional radia-
tion using standard external beam techniques. Salvage surgery
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with photon beams [7], and reirradiation with neutron beam
therapy [8] are strategies that have been utilized with limited
success.
Stereotactic radiosurgery (SBRT) represents an appealing
option for the management of salivary gland tumors either as a
means of dose escalation or for reirradiation of recurrent
tumors. SBRT uses multiple convergent beams with various
targeting techniques to deliver highly conformal treatment
accurately. Gamma knife-based SBRT technologies, which
require external frame-based fixation devices, have been pre-
viously used in the retreatment of recurrent salivary gland
tumors involving the skull base [9, 10]. Local control rates
were reported at 100% and 75% [9, 10]. The CyberKnife
SBRT system (Accuray, Inc., Sunnyvale, CA) allows confor-
mal treatment of sites throughout the head and neck region.
This system uses real-time image guidance for targeting with-
out rigid external fixation [11]. Multiple treatment sessions
can be used, potentially reducing late normal tissue toxicity
via dose fractionation. We report our institutional experience
with fractionated SBRT irradiation of salivary gland cancers,
addressing feasibility, safety, and outcomes.
Patients and methods
Patients
Eligible patients were diagnosed with recurrent malignant
salivary gland tumors and were treated with definitive SBRT
reirradiation either as a primary or adjuvant modality at the
Georgetown University Hospital between September 2003
and March 2011. All patients had histologically proven dis-
ease. Details of the previous radiation therapy were available
for all patients with prior history of salivary gland irradiation.
The data were reviewed under an institutional review board-
approved retrospective protocol. A total of 22 patients who
met entry criteria were identified. Four patients were lost to
follow-up and were excluded from the study. The final group
consisted of 18 patients with prior salivary gland tumor irra-
diation whose recurrent tumors either were unresectable or
had gross residual disease or positive margins postoperatively.
Two of the 18 patients received SBRT as part of their primary
treatment, and a second course of SBRT for their local recur-
rence was included in local control and progression-free sur-
vival analysis but excluded from the overall survival analysis.
Before the treatment, patients' cases were reviewed at the
multidisciplinary head and neck tumor board. When feasible,
patients underwent surgical resection. Other than determining
presence or absence of gross disease, no patient selection was
performed. Radiosensitizing concomitant chemotherapy was
administered at the discretion of the treating medical oncolo-
gist. The most common chemotherapy was carboplatin
administered in three cycles. The first cycle was given 1 week
prior to the initiation of the radiation treatment followed by
another cycle administered concurrently with the treatment. The
third cycle was given the week following radiation treatment.
Fractionated stereotactic body radiation treatment
The CyberKnife SBRT system (Accuray, Inc., Sunnyvale, CA)
uses a 6-MV X-band linear accelerator mounted on a fully
articulated robotic arm. During treatment, two orthogonally
positioned x-ray detectors provide real-time imaging of bony
anatomy allowing for intrafraction movement correction. Treat-
ment was generally administered on an outpatient basis with
each treatment lasting approximately 45–90 min. Most of the
patients received their treatments over the course of 7 days,
consecutive with the exception of holidays or weekends.
Patients were immobilized in the supine position with an
Aquaplast facemask (WRF/Aquaplast Corp., Wyckoff, NJ).
All patients underwent a treatment planning computed
tomography (CT) scan, fused with a fluorodeoxyglucose-
positron emission tomography (FDG-PET) scan with 1.0-
mm-thick slices. In all cases, magnetic resonance imaging
(MRI) scans with VIBE sequence and 1-mm slices were also
used in planning. The MRI and PET images were then fused
with that of the simulation CT scan for treatment planning.
The gross tumor volume (GTV) was reconstructed based on
the information obtained from both the PET and the MRI
together. The PET-GTV was usually contoured to the halo.
The sum of both the PET-contoured volume and the MRI-
contoured volume defined the GTV. Once the GTV was
contoured, an expansion was done ranging from 2 to 10 mm
depending on the pathologic margin status and proximity to
critical structures to define the clinical tumor volume. No
additional margin was added for the planning target volume
(PTV). In postoperative cases, the preoperative MRI was also
fused with the postoperative PET and MRI, and the sum of
all volumes defined the postoperative PTV. In seven cases,
adjacent soft tissue and immediate draining lymph nodes
were targeted as a separate PTV. In patients who under-
went surgical resection, the PTV encompassed the entire
surgical bed when feasible. The median reirradiation dose
was 30 Gy but varied between 21 and 40 Gy depending on
prior dose, interval to reirradiation, and tumor burden.
Similarly, the median dose per fraction was 5 Gy and
varied between 2 and 7 Gy. Of these fractionation schemes,
the most frequently used was 30 Gy in five fractions (seven
patients). For neck irradiation, ipsilateral neck irradiation was
given as five fractions, 7 Gy each for a total dose of 35 Gy.
Inverse planning was used to determine the dose to the
target volume while minimizing the dose to normal tissue.
All planning was completed within 1 week of imaging,
and typically, patients initiated treatment in 2–3 weeks
after imaging depending on chemotherapy coordination.
Treatment was generally completed within 7 days of
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initiation, consecutive with the exception of holidays or
weekends.
Post-treatment follow-up
Patients typically underwent a post-treatment surveillance with
an MRI scan 3 months after the completion of SBRT and then
every 6 months thereafter (with a FDG-PET/CT scan and
MRI). Radiographic imaging was done on follow-up to mon-
itor disease recurrence locally, regionally, or distantly. For
those with gross disease, PET and MRI were used to monitor
“response” to treatment as well as regional and distant metas-
tases. For those without evidence of gross disease on treatment
initiation, radiographic evaluation was done to monitor disease
recurrence locally, regionally, or distantly. Clinical examina-
tion was conducted at the same interval, with biopsy as indi-
cated. Acute and late toxicity were graded using the Radiation
Therapy Oncology Group (RTOG) scoring criteria.
Statistical analysis
Progression-free survival (PFS) was defined as the time from
the first day of SBRT treatment to local/distant failure or last
follow-up in living patients without evidence of recurrence/
progression. Locoregional control (LRC) was defined similarly
except that death and distant failure were not considered
events. Patients were censored at the time of death. Overall
survival (OS) was the time from SBRT treatment until death or
last follow-up. PFS and LRC were evaluated among the subset
of patients treated definitively. OS was evaluated among the
subset treated definitively and for all patients. Interpretation of
available FDG-PET/CT, MRI, and CT scans with correlative
clinical examinations was used to assess for response of the
treated lesion 2–3 months after SBRT. Complete response was
defined as no evidence of disease in the treatment volume by
both radiographic and direct clinical examination. No response
was defined as absence of marked change or increase in the
treated lesion. Partial response was defined as not meeting the
criteria for complete response or no response. Log rank tests
and Cox regression models were used to evaluate the associa-
tion between clinical factors and each survival outcome. The
independent variables considered were surgery (yes, no), nodal
status (yes, no), presence or absence of gross disease (yes, no),
SBRT dose (<35 Gy, ≥35 Gy), interval to reirradiation
(<12 months, > 12 months), grade (low, medium, high), con-
current chemotherapy (yes, no), nodal stage per the AJCC
staging system, age in years, size in centimeters, SBRT dose
in grays, and cumulative dose in grays. The presence of
positive margins was coded as absence of gross disease since
most patients had one or the other. Multivariate analysis was
conducted for selected factors while adjusting for age or
presence of gross disease in the Cox model. Kaplan–Meier
plots are presented for selected significant factors. For long-
term toxicity analyses, dysphagia (present, absent), fibrosis
(present absent), and soft tissue or bone radionecrosis (present,
absent) were the dependent variables. Correlation of toxicity
variables with SBRT dose was done using logistic regression.
The correlation between the presence or absence of diabetes
and development of soft tissue necrosis was examined using
chi-square test. Analyses were performed in SAS version 9.2
(SAS Institute Inc., Cary, NC).
Results
Patient characteristics and disease presentation
Baseline patient and disease characteristics are listed in
Table 1. Median patient age at the time of treatment was 68,
13 patients were males, and the majority of the tumors were of
the parotid glands. Themost common histopathologic subtype
was squamous cell carcinoma while adenocystic, acinic, and
adenocarcinoma were equal (Table 1). Although the majority
of the patients [11] had N0 disease, five patients had N2
disease.
Table 1 Patient characteristics
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Treatment characteristics
Treatment characteristics are presented in Table 2. The majority
of [10] patients did not undergo surgery (seven did not, three
attempted). Among the eight patients that did, all had positive
margins. Of the seven patients with nodal disease, four under-
went ipsilateral neck dissection, and three did not. Four of the
patients (one definitive and three adjuvant) received ipsilateral
neck irradiation. Adverse pathologic included three (17%)
patients with perineural involvement, four (22%) had facial
nerve involvement, and two (11%) with lymphovascular
involvement or extracapsular extension (Table 2). The major-
ity of the patients [11] did not receive chemotherapy (Table 2).
Treatment doses were discussed under the “Fractionated
stereotactic body radiation treatment” section above and are
also shown in Table 2.
Clinical outcomes and prognostic factors
With a mean follow-up of 20 months (range, 0–88 months;
median follow-up, 12 months), the median OS, PFS, and LRC
were 11.5, 3.5, and 5.5 months (Table 3; Figs. 1, 2, and 3). The
2-year OS, PFS, and LRC rates were 39%, 24%, and 53%,
respectively (Table 3). Crude survival outcomes are also shown
in Table 3. Forty-four percent failed locoregionally, 44% failed
distantly, and the cancer-specific mortality was 50% (Table 3).
Univariate analysis revealed that presence of gross disease and
the interval to reirradiation were negatively correlated with
overall survival (p<0.05, Table 4 and Fig. 4). On multivariate
analysis after adjusting for age, interval to reirradiation (p0
0.0197; HR, 0.0650, 95% CI 0.0066–0.6389), gross disease
(p00.0446; HR, 4.5354, 95% CI 1.0446 to 19.69), and tumor
volume at the time of reirradiation (p00.0412; HR, 1.0034,
95% CI 1.0022 to 1.0066) were significant predictors of OS.
On multivariate analysis, tumor volume at the time of reirra-
diation was also statistically correlated with progression-free
survival (0.0329; HR, 1.0038, 95% CI 1.0003 to 1.0073). A
statistically significant correlation was seen between SBRT
dose and LRC with doses above 35 Gy yielding better LRC
rates (p<0.05). However, it is important to note that the analy-
ses is solely based on four events, since only four patients were
treated with doses greater than 35 Gy, which limits the ability to
draw any definitive conclusions.
Toxicity
Six patients experienced RTOG grade 1 to 3 acute toxicity,
including mucositis, dermatitis, and nausea. These complica-
tions were generally transient and resolved with conservative
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management. One patient (3%) experienced RTOG grade 4–5
acute toxicity as he developed aspiration pneumonia within a
month from initiation of treatment and died as a result. Two
patients (11%) developed fibrosis. Both had surgical resection
with neck dissection in addition to the radiation treatment. Six
patients (33%) experienced dysphagia. None, however,
required a feeding tube. Severe late radiation-induced toxicity
was limited to soft tissue necrosis (STN) seen in four patients
(22%). All of these patients were salvaged by surgical recon-
struction. There was a statistically significant correlation
between SBRT dose, as well as cumulative dose, and the
development of STN (p00.004, p<0.001). Plots of the STN
vs. cumulative dose revealed that the risk of STN arises near
90 Gy, but as there are only four observations of STN in the
group, a definitive conclusion cannot be made. There also
appears to be a statistically significant correlation between
diabetes and development of soft tissue necrosis (p00.025)
using chi-square test.
Discussion
The present study described our recent experience with the
reirradiation of salivary gland cancer patients using fractionated
stereotactic body radiosurgery. Our work focused on a small
subset of this rare disease, those that have recurred in a previ-
ously irradiated site. Published reports of definitive radiothera-
py for recurrent salivary cancer demonstrate generally poor
locoregional control rates [6–8, 10]. In previously irradiated
tissue, the proximity to critical structures often prohibits the
delivery of additional radiation using standard external beam
techniques. Fractionated SBRT allows for delivery of highly
conformal treatment of targets that are in close proximity to
critical structures. Fractionation has been hypothesized to
improve the therapeutic ratio, thereby reducing the risk of late
complications potentially associated with a large single dose
[11]. The use of nonhomogeneity to selectively vary the dose
at different sites within the target is another added benefit of
hypofractionated radiosurgery as it provides the flexibility to
steer a hot spot to the desired target and away from critical
structures such as the mandible while treating previously
irradiated parotid tumors [11]. In other words, a steeper dose
gradient is constructed to answer the clinical need.
Comparative analysis of using daily fractionated SBRT for
reirradiation compared to other modalities or regimens is
somewhat challenging given the heterogeneity of this patient
population. In this study, the reirradiation group comprised
patients with very high-risk adverse features. One third of the
patients were deemed inoperable, and half either had gross
disease or positive margins. With a mean follow-up of
19 months, 44% of the patients failed locally with an actuarial
local control rate of 53% at 2 years. This is comparable to
other studies using neutron therapy for recurrent salivary
gland malignancies, which reported a 5-year local control rate
of 26% [8]. Forty-four percent of the patients developed
distant failure, and 16% had both local and distant failures
Fig. 1 Overall survival for SBRT reirradiation patients (n016)
Fig. 2 Locoregional control for SBRT reirradiation patients (n018)
Fig. 3 Progression-free survival for SBRT reirradiation patients (n018)
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[8] consistent with other reports of distant failure representing
the dominant pattern of failure [7, 12].
Prognostic analysis revealed, not surprisingly, that presence
of gross disease and shorter interval to reirradiation treatment
are negative predictors of overall survival on both univariate
and multivariate analyses. This is consistent with the results of
randomized phase III European multi-institutional trial show-
ing a benefit for reirradiation in the postoperative setting after
salvage surgery in patients with high-risk surgical features
[13]. On multivariate analysis, there was also a statistically
significant correlation between the volume of disease at the
time of reirradiation and overall survival. The importance of
tumor bulk in predicting survival outcome has also been
shown in other studies of reirradiation of head and neck
cancers [14, 15].
It had been reported that adjuvant chemotherapy admin-
istered concurrently with reirradiation patients improved
locoregional control rates as well as distant disease control
[8, 16]. A number of phase I and II trials have investigated
systemic therapy withmixed results [16]. Recently, concurrent
chemoradiation has been shown to improve LRC and PFS in
retrospective series [7, 17, 18]. In our series, no statistically
significant correlation was seen on either univariate or multi-
variate analysis perhaps due to the fact that only 39% of the
patients received chemotherapy.
It has been established that the higher the dose that can be
safely delivered, the higher the probability of disease control
[19–21]. Unger et al. have shown that for stereotactic radio-
surgery, doses over 30 Gy were associated with improved
locoregional outcomes [21]. When we first initiated SBRT
reirradiation of salivary gland tumors, we were uncertain
about tolerance and late effects for hypofractionated reirradia-
tion. We therefore started cautiously with doses in the 21–25-
Gy range. By the time most patients were treated, we had
adopted 30–35 Gy for microscopic disease and 35–40 Gy for
gross disease with margins as delineated above and with PET/
CT and MRI volumes. In our series, a statistically significant
correlation was seen between SBRT dose and LRCwith doses
above 35Gy yielding better LRC rates. However, as mentioned
earlier, the analysis is solely based on four events, which limits
the ability to draw any definitive conclusions.
A higher treatment dose was associated with a higher
incidence of STN in patients treated with cumulative doses
above 90 Gy. Nevertheless, all were successfully salvaged
with surgical debridement and reconstruction. It is important
to note, however, that since also only four patients experi-
enced toxicity, the data remain inconclusive. In other studies,
severe late-term radiation toxicity has been reported on the
Table 4 Univariate analysis.
Hazard ratio analysis of survival
outcomes for prognostic factors.
Abbreviations Overall survival
(OS), progression-free survival
(PFS), and locoregional control
(LRC), p-value (p), hazard ratio
(HR), 95% confidence interval
(95% CI)
OS LC PFS
Surgery p 0.3806 0.3458 0.8091
HR 0.5648 2.2152 1.1642
(95% CI) (0.1584–2.0138) (0.427–11.477) (0.3413–3.9711)
Gross disease p 0.0270 0.4709 0.6299
HR 0.198 0.5460 1.3462
(95% CI) (0.047–0.832) 0.1063 to 2.8054 (0.4043–4.4822)
Age p 0.1192 0.1418 0.3598
HR 1.039 1 .044 1.020
(95% CI) (0.990–1.091) (0.986–1.107) (0.978–1.065)
Nodal status p 0.6357 0.3707 0.2565
HR 1.159 1.463 1.516
(95% CI) (0.630–2.130) (0.636–3.363) (0.739–3.113)
Reirradiation interval p 0.0159 0.8525 0.1669
HR 0.0659 1.2421 0.3571
(95% CI) (0.0073–0.5947) (0.1279–12.0619) (0.0835–1.5267)
Fig. 4 Overall survival by interval to reirradiation
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order of 30% with photon radiotherapy and 69% with neutron
radiotherapy [8]. Our finding of statistical correlation between
soft tissue necrosis and presence of diabetes is hypothesis
generating and may be related to poor wound healing, but
warrants further investigation.
Conclusion
This study has demonstrated the feasibility of using fraction-
ated SBRT reirradiation of recurrent tumors with response rates
comparable to other treatment modalities. At early follow-up,
treatment was generally well tolerated, but caution needs to be
exercised with higher doses to prevent STN. Our retrospective
review is, however, limited by potential selection bias, sample
size, and heterogeneous patient population and treatment
parameters. Future studies with larger sample size, longer
follow-up, and less histological variability are warranted.
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